Advertisement
Advertisement



HIV/AIDS NEWSROOM

The Rise of Broadly Neutralizing Antibodies

FDA to Evaluate Potential Risk of Neural Tube Birth Defects With HIV Medicine Dolutegravir (Juluca, Tivicay, Triumeq)

This Week in HIV Research: Little Promise of Anal Protection From Adult HPV Vaccination

With Only 15% of Diagnosed HCV Patients Receiving Treatment, the Non-Profit I-MAK Hopes to Shift the National Conversation on Drug Pricing

Why Experienced HIV/ID Doctors Leave Clinical Practice

PrEP Training for Primary Care Providers Could Help Expand Its Reach

This Week in HIV Research: Heavier Health Burdens Begin Before Diagnosis

Is Ending the HIV Epidemic Possible, and If So, How? IAPAC Meeting in Geneva Takes Stock of Progress and the Road Ahead

HIV's Largely Ignored Relative, HTLV-1, Has Prevalence Rates of Up to 40% in Some Remote Areas

Advances in Two-Drug Antiretroviral Regimens

NIH Clinical Trial to Track Outcomes of Kidney Transplantation From HIV-Positive Donors to HIV-Positive Recipients

State-Level PrEP Utilization Data Now Available From AIDSVu

Why Does HIV Pose a Greater Threat to Women's Hearts?

This Week in HIV Research: The Ubiquity, and Diversity, of Substance Use

If Your Patient Has Gonorrhea, Make Sure You Treat Them With Ceftriaxone Plus Azithromycin

The Patient as Partner

Overview of HCV Disease Progression



Advertisement